How Long Does Xeomin Last? Onset, Duration, and What to Expect

Xeomin (incobotulinumtoxinA) is an FDA-approved botulinum toxin type A product used to temporarily improve the appearance of moderate to severe glabellar frown lines, and — following a July 2024 label expansion — the first and only neurotoxin approved for the simultaneous treatment of upper facial lines including forehead lines, frown lines, and crow's feet. Like other neuromodulators, its effects are temporary. The FDA label states that the typical duration of effect is up to 12–16 weeks (approximately 3–4 months), though individual patients may experience shorter or longer results.

This guide covers the onset timeline, the clinical evidence on duration, factors that change how long Xeomin lasts, and how it compares to Botox, Dysport, and Daxxify.

When Xeomin starts working: onset timeline

The FDA label for Xeomin states that "the median onset of XEOMIN treatment effect occurs within seven days after injection." In practice, most patients begin to see softening of treated lines within 3–5 days, with full results visible at 7–14 days.

A head-to-head study comparing Xeomin to Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA) for glabellar frown lines found that onset timing was comparable across all three products. In that study, investigators noted decreased muscle activity in all Xeomin-treated subjects by day 4.

A separate peer-reviewed study published in Clinical, Cosmetic and Investigational Dermatology reported that incobotulinumtoxinA showed onset as early as 2–4 days post-injection, with some patients reporting visible effect by day 2.

Realistic expectations for onset:

Plan treatment at least two weeks before any important event to allow the full effect to develop.

How long Xeomin lasts: the evidence

The FDA label for Xeomin's glabellar lines indication describes a typical duration of effect of up to 12–16 weeks. The clinical trials submitted for FDA approval (Studies GL-1 and GL-2) followed 547 patients for 120 days after a single 20-unit treatment, with investigators assessing efficacy at maximum frown on day 30 and beyond.

Beyond the label, published clinical evidence provides additional context:

• A peer-reviewed study on onset, longevity, and patient satisfaction with incobotulinumtoxinA for glabellar frown lines reported duration of effect lasting more than 5 months in a substantial proportion of patients. The study described this as "desirable characteristics that contribute to patient satisfaction."
• In the head-to-head comparison study (XEOMIN vs BOTOX vs DYSPORT, 180 subjects), median duration was approximately 150 days (roughly 5 months) for female patients receiving Xeomin and approximately 120 days (roughly 4 months) for male patients. This was comparable to both Botox and Dysport in the same study.
• For therapeutic indications, Xeomin's label reports longer durations in some clinical contexts. In blepharospasm trials, the median treatment interval was 19.9 weeks (approximately 5 months). These therapeutic doses and areas are not directly comparable to cosmetic facial injections, but they demonstrate that incobotulinumtoxinA's pharmacological duration can extend well beyond 12 weeks.

The realistic range for most cosmetic patients is 3–4 months, with some patients reporting 4–5 months, particularly after consistent retreatment over time.

Factors that affect how long Xeomin lasts

1. Treatment area

Areas with more muscular movement tend to metabolize botulinum toxin faster.

• Forehead lines: Often last 3–4 months. The frontalis muscle has moderate activity.
• Glabellar frown lines (the "11s"): Typically last 3–4 months. The corrugator and procerus muscles are strong and active.
• Crow's feet: May last 2–3 months. The orbicularis oculi is in constant use during blinking and facial expression.
• Masseter (jaw slimming): Off-label use can last 3–6 months, but requires higher doses and results vary substantially by muscle bulk.

2. Dose

Higher doses generally produce longer-lasting effects, up to a point. The FDA-approved dose for glabellar lines is 20 units. The upper facial lines approval (forehead + glabellar + crow's feet simultaneously) uses a total of 64 units. Providers who use doses at the lower end of the range may see results fade sooner.

3. Individual metabolism

Patients with faster metabolisms — younger patients, very active individuals, those with higher muscle mass — may process the toxin more quickly. This is clinical observation rather than a formal FDA-label claim, but it is a consistent pattern reported across botulinum toxin products.

4. Treatment history and consistency

Patients who receive neuromodulator treatments on a consistent schedule (every 3–4 months) often report that results last longer over time. The treated muscle becomes conditioned to reduced activity, which may extend the functional duration. There is no high-quality randomized data confirming this effect specifically for Xeomin, but it is a common clinical observation across all botulinum toxin products.

5. Antibody formation

One theoretical advantage of Xeomin is that it is formulated without accessory (complexing) proteins — it contains only the purified neurotoxin and human albumin/sucrose as excipients. The clinical significance of this is debated, but the theory is that fewer foreign proteins may reduce the risk of neutralizing antibody formation, which can cause treatment failure over time. In clinical trials for glabellar lines, no patients developed neutralizing antibodies after Xeomin treatment. This does not mean antibody formation is impossible, but the observed rate was zero in the studied population.

Xeomin duration compared to other neuromodulators

Xeomin's duration is clinically comparable to Botox and Dysport. The head-to-head data supports this: in the 180-subject study, median duration for female patients was approximately 150 days for Xeomin, approximately 140 days for Botox, and approximately 140 days for Dysport. The differences were not clinically meaningful.

Daxxify is the only neuromodulator with substantially longer FDA-reported duration (median ~6 months), achieved through a proprietary peptide-stabilized formulation. Patients specifically seeking longer intervals between treatments may prefer Daxxify, though it tends to cost more per session.

What to ask your provider about Xeomin duration

1. What dose are you using, and is it at the FDA-approved range? Under-dosing is the most common reason for short duration. For glabellar lines, 20 units is the labeled dose. For full upper facial treatment, 64 units is the recommended total.
2. How long do your patients typically maintain results? Provider-specific data is more useful than published averages, because technique, dose, and patient population all affect outcomes.
3. Should I switch from Botox/Dysport to Xeomin? If you have been receiving another neuromodulator and notice diminishing results over time, the "naked" formulation of Xeomin (without accessory proteins) is sometimes discussed as an alternative. There is no guarantee it will perform differently for any individual patient, but some providers recommend trying it if response to other products has waned.
4. When should I book my next appointment? For most patients, scheduling at 3–4 months is standard. Booking earlier (at 10–12 weeks) may allow for consistent muscle weakening over time, potentially extending the interval in subsequent treatments.

How to prepare for your Xeomin appointment

• Stop blood thinners and alcohol one week before. Avoid aspirin, ibuprofen, fish oil, vitamin E, and alcohol for 5–7 days before treatment to minimize bruising. Do not stop any prescribed medication without your prescribing physician's approval.
• Tell your provider about all medications and supplements. Some medications and supplements increase bruising risk. A complete list helps the provider plan injection placement.
• Arrive with a clean face. Remove makeup, sunscreen, and skincare products before the appointment. Most providers will cleanse the area again, but starting clean reduces irritation.
• The appointment is brief. A typical Xeomin treatment for the upper face takes approximately 10–20 minutes. The provider examines your facial anatomy, marks injection sites, and performs the injections using a fine needle.

How to make Xeomin last longer

There is no scientifically proven way to extend the pharmacological duration of botulinum toxin. However, several practices are commonly recommended by providers to support consistent results:

Aftercare (first 24 hours)

• Do not lie flat for 4 hours after treatment. This is a standard post-injection recommendation to reduce the theoretical risk of product migration.
• Do not rub or massage the treated areas for 12–24 hours. Physical manipulation could displace the toxin from the intended muscles.
• Avoid strenuous exercise for 24 hours. Elevated heart rate and blood flow may theoretically affect distribution.
• Avoid heat exposure (saunas, hot yoga, direct sun) for 24 hours for the same reason.
• Avoid alcohol for 24 hours to minimize additional swelling or bruising.

Ongoing maintenance

• Schedule consistent treatments. Patients who maintain a regular 3–4 month schedule often report longer-lasting results over time. The treated muscle becomes conditioned to reduced activity, which may extend the functional duration between sessions.
• Use daily sunscreen. UV damage accelerates collagen breakdown and skin aging, which can make wrinkles appear more prominent even when the toxin is still active. Sunscreen protects the underlying skin quality.
• Avoid smoking. Smoking accelerates collagen degradation and skin aging, and may affect how quickly the body metabolizes the toxin. This is based on clinical observation rather than Xeomin-specific clinical trials, but it is a consistent pattern across botulinum toxin products.

Lifestyle factors that may shorten duration

• High-intensity exercise. Very active patients — particularly endurance athletes and those with high muscle mass — may metabolize botulinum toxin more quickly. This is clinical observation, not a labeled claim.
• Higher muscle mass in treated areas. Stronger facial muscles may require more toxin and may process it faster. Men, who tend to have greater muscle mass in the jaw and brow, sometimes report shorter duration at the same dose.

Who is a good candidate for Xeomin

Xeomin is appropriate for adults with moderate to severe dynamic wrinkles — lines that appear during facial expression (frowning, squinting, raising the eyebrows) — who want a non-surgical approach. It is also used preventatively in younger patients to delay the formation of static wrinkles (lines visible at rest).

Xeomin may be particularly suitable for patients who:

• Have received other neuromodulators and noticed diminishing response. The "naked" formulation (no complexing proteins) is sometimes discussed as an alternative when patients suspect antibody-mediated treatment failure, although this is rare and should be evaluated by a provider.
• Prefer a formulation with fewer excipients. Xeomin contains only the active neurotoxin, human albumin, and sucrose. Patients who prefer a minimalist formulation may find this relevant.
• Want simultaneous treatment of multiple upper facial areas. Since July 2024, Xeomin is the first and only FDA-approved neurotoxin for simultaneous treatment of forehead lines, glabellar frown lines, and crow's feet in a single session (total 64 units).

Xeomin is not appropriate for patients who are pregnant or breastfeeding, have active infections at the injection site, have known hypersensitivity to botulinum toxin or any ingredient in the formulation, or have underlying neuromuscular disorders such as myasthenia gravis or Lambert-Eaton syndrome.

Sources

• XEOMIN (incobotulinumtoxinA) Prescribing Information. Merz Pharmaceuticals LLC. Updated 2023. FDA label reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125360s097lbl.pdf
• XEOMIN Aesthetic. "Clinical Evidence & Trial Data." Merz Aesthetics. https://www.xeominaesthetic.com/professionals/why-xeomin/clinical-evidence
• Rappl T et al. "Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines." Clin Cosmet Investig Dermatol. 2013;6:211-219. https://pmc.ncbi.nlm.nih.gov/articles/PMC3116796/
• Jandhyala R. "Comparative efficacy and duration of botulinum toxin products for glabellar lines." J Drugs Dermatol. 2013.
• Merz Aesthetics. "FDA Approves Merz Aesthetics' Xeomin for Simultaneous Treatment of Upper Facial Lines." 2025. https://www.pharmexec.com/view/fda-approves-merz-aesthetics-xeomin-simultaneous-treatment-upper-facial-lines
• XEOMIN Dosing & Administration. Merz Aesthetics HCP site. https://hcp.xeomin.com/healthcare-professionals/administering-xeomin